EyePoint Pharmaceuticals Welcomes Reginald J. Sanders to Board
EyePoint Pharmaceuticals Strengthens Leadership with New Board Member
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), based in Watertown, Massachusetts, is dedicated to improving the lives of patients suffering from serious retinal diseases through the development and commercialization of innovative therapeutics. Recently, the company announced the appointment of esteemed retina specialist Reginald J. Sanders, M.D., FASRS, to its Board of Directors.
Welcome from the Board Chair
Göran Ando, M.D., Chair of EyePoint's Board, expressed his excitement about Dr. Sanders' addition to their team. He remarked, "Scientific and medical leadership underpin our mission to develop innovative therapeutics for patients with serious retinal diseases. Dr. Sanders, as a prominent leader in the retina community, will be an invaluable asset to our Board. With global phase 3 pivotal trials for wet AMD underway and positive interim results for our Phase 2 trial in diabetic macular edema, Dr. Sanders’ substantial clinical experience and unique business development skills will be critical to our progress."
Dr. Sanders' Impressive Background
Dr. Sanders expressed his honor to join the EyePoint Board at such a crucial time. "Having dedicated my career to providing the highest quality of comprehensive care to my patients, I am impressed by the robust clinical data from EyePoint and the significant potential of DURAVYU for serious retinal diseases. The team's excellent track record in execution is commendable, and I look forward to collaborating closely with the talented management and Board members to deliver revolutionary treatments to patients."
A Pioneer in Ophthalmology
As a distinguished retina specialist, Dr. Sanders has made notable advancements in the field of ophthalmology. He has served on the board of Prism Vision Group (PVG) and recently held the position of President of the American Society of Retina Specialists (ASRS). His career with the Retina Group of Washington (RGW) has played a significant role in establishing it as the largest practice of retinal specialists in the United States.
Dr. Sanders has also built a strong reputation in education and research, with over 50 papers and presentations to his name, and has contributed to the development of new retinal treatments through comprehensive studies.
Honors and Recognition
His contributions to the field have earned him numerous accolades, including election as a charter inductee into the Retina Hall of Fame and the Packo Service Award for outstanding service to the Society. Dr. Sanders trained at renowned institutions such as Yale-New Haven Hospital and Wills Eye Hospital and completed a fellowship in Vitreo-retinal Diseases and Surgery at the Massachusetts Eye and Ear Infirmary/Harvard Medical School, holding an M.D. from Yale University and a B.S. from the University of Virginia.
About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing therapies for patients with serious retinal diseases. The company utilizes its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate, DURAVYU™ (formerly EYP-1901), is an investigational treatment aimed at VEGF-mediated retinal diseases and is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), which is a leading cause of vision loss among older adults in the United States. In addition, there is an ongoing Phase 2 clinical trial for diabetic macular edema (DME), with topline data anticipated in the near future.
EyePoint's pipeline also includes EYP-2301, a TIE-2 agonist meant to improve outcomes in serious retinal diseases, highlighting the company's commitment to leveraging proven Durasert technology, which has established a strong safety profile across multiple FDA-approved products. The company is strategically positioned to address critical health issues affecting vision by innovating therapies that could vastly improve patient outcomes.
Investors and Media Contacts
For inquiries, investors can reach out to Christina Tartaglia at Precision AQ via direct line 212-698-8700 or through email. Media inquiries can be directed to Amy Phillips at Green Room Communications at 412-327-9499.
Frequently Asked Questions
Who is Reginald J. Sanders?
Reginald J. Sanders, M.D., FASRS is a renowned retina specialist and the newest member of the Board of Directors of EyePoint Pharmaceuticals.
What is EyePoint Pharmaceuticals known for?
EyePoint Pharmaceuticals is known for developing innovative therapeutics targeting serious retinal diseases and leveraging advanced drug delivery technologies.
What therapy is DURAVYU targeting?
DURAVYU is primarily targeting VEGF-mediated retinal diseases, specifically focusing on conditions like wet age-related macular degeneration and diabetic macular edema.
What recent accomplishments has EyePoint achieved?
EyePoint has initiated global phase 3 pivotal trials for wet AMD and received positive interim data from its Phase 2 trials for DME.
How can I reach out for investor inquiries?
Investors can contact Christina Tartaglia at Precision AQ for inquiries related to EyePoint Pharmaceuticals.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
